Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Antex Biologics (ANTX) -- Ignore unavailable to you. Want to Upgrade?

To: Joseph Wisnowski who wrote (795)	3/31/1998 7:43:00 PM
From: RIP	Read Replies (1) \| Respond to of 1476

Joe, I just finished reading it myself. I guess my impatience to call Terry was just in time. Your question is an extremely good one. I too feel that reverse splits have been bad for a company when they are trying to MAINTAIN a listing. They have almost all failed. But in this case (and I own a large position in ANTX...in it for 2 years like Mike and also have accumulated...so you can call me biased) I think it is to our advantage so that ANTX can begin to tell their story. With Phase III around the corner on Campy and II on H-Pylori, a listing on the market will allow them to be looked at by small cap mutual funds and institutions. Most have legal contracts with clients on their funds not to buy anything below $5. I feel they will get the stock to $6-7 with the split and then announce these clinical advances. In any case, I am long on ANTX. I know the management and feel very comfortable with the company. Risk in this field is always a problem, but they have strong strategic partnership with two major drug companies and the US Navy. I like my chances and will accumulate on any dips. I really feel this is going to be a BIG year...boy I hope so. Rip